NCT01286974

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Disposition of [14C]ABT-869 in Patients With Solid Tumors Following a Single Oral Dose Administration

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Abbott · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.

Detailed description

This study is designed to assess the mass balance of \[14C\]linifanib and the metabolic profiles of linifanib in 4 subjects with advanced solid tumors following a single oral dose. Subjects may continue on linifanib after completion of the metabolism study. The results of this study will determine the exposure of major metabolites and excretion pathway(s) of the parent drug and metabolites of linifanib in humans.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	[14C]linifanib	\[14C\]linifanib, single administration, oral liquid
DRUG	ABT-869, linifanib	linifanib once a day (QD), oral tablet

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-08-01
• Completion: 2012-09-01
• First posted: 2011-02-01
• Last updated: 2012-09-21

Locations

2 sites across 1 country: United States